IDRA is up 680% YOY through three secondary offerings and still no advanced stage clinical trial results yet. All of this driven by funds and insiders. You think this has potential? Just wait until we actually get advanced trial results and drugs to market. Anybody questioning their science or shorting this stock is a brain dead idiot. At $100 per share Brenner's options are worth $60 million I would say that's the type of money he came here for. You don't get a BS from Yale, MD from Duke, and MBA from Harvard for nothing.
Excellent thread guys. Baker Bros is a huge factor here, but I think those two execs they brought on from Genzyme really tell you where Idera is headed. I think $40-50 a share by the end of this year is achievable.
Nice , you are very close to celebrate the wisdom of reading inbetween the lines
Already you must have done 150 - 200 percent on your holding , and it the party did not start yet
This by far beating all star stock pickers
Agree. I would just ignore questions coming on msg board regarding science and potential. If people on sideline don't want to get in before monday, it's their problem. We will see IDRA getting into next level after Tuesday.
At $100 per share, this is a $6 Billion company. At Genzyme, also focused on Orphan drugs, these guys were bought out in 2011 for $20 Billion. Brenner, it should be noted, had already moved on from Genzyme by then, so he's probably the hungriest of the four. I think they're thinking bigger than you are.
There is a flaw in all of the talk about them now being focused on orphan indications. If they want to treat several diseases by sticking a cork in TLR8 for example, it has to be essentially the same cork. They can make an arbitrary small change to make a version that they call the orphan drug version but it will still work the same way. This may be worth doing to get an advantage with the FDA or partners for the short term. After the mass market version gets approved for psoriasis or whatever and can then be used off label, why would anyone spend 10 times more or whatever for the orphan version. They would not have the pricing power for a typical orphan drug.